Fig. 2From: A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinomaTrial profile. TP, paclitaxel followed by cisplatinBack to article page